CG Oncology's Participation at the Annual EAU Congress
CG Oncology, Inc. (NASDAQ: CGON), a company focused on developing innovative antibiotic immunotherapy for bladder cancer, is gearing up for an impactful presence at the upcoming Annual European Association of Urology (EAU) Congress. This prominent event, which draws thousands of medical professionals, will be held in Madrid. CG Oncology plans to present a late-breaking abstract on BOND-003 Cohort C alongside three other relevant posters that delve into the details of cretostimogene grenadenorepvec, an investigational oncolytic therapy.
Key Presentations and Abstracts
Among the highlights at this year's congress are several key presentations regarding cretostimogene grenadenorepvec. One significant presentation includes:
Updated Clinical & Translational Results: A focus on BOND-003 Cohort C, which is a phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer that includes carcinoma in situ.
Session Details:
Late Breaking Abstract Number: LB12
Presenter: Trinity J. Bivalacqua, M.D., a notable expert in Urology and Oncology. The presentation is scheduled to take place on March 24, 2025, at Pink Area N101, Ifema, Madrid.
Translational Correlates from Clinical Trials
Another notable presentation will be exploring the translational correlates leveraging urinary genomic disease burden to assess cretostimogene grenadenorepvec, based on insights from the BOND-003 and CORE-001 trials. Presented by Sharada Mokkapati, Ph.D., this presentation also addresses the breakthrough nature of these findings in the context of non-muscle invasive bladder cancer treatment.
Ongoing Research Initiatives
In addition, CG Oncology will present findings from BOND-003 cohort P, a multi-national, single-arm study evaluating the effectiveness of cretostimogene grenadenorepvec for treating high-risk, papillary-only, BCG-unresponsive non-muscle invasive bladder cancer. This research demonstrates CG Oncology's commitment to finding viable treatment options for patients who do not respond well to conventional therapies.
About Cretostimogene Grenadenorepvec
This investigational drug is administered intravesically and functions as an oncolytic immunotherapy, targeting patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who do not respond to Bacillus Calmette-Guerin (BCG) therapy. The clinical trials, such as PIVOT-006, highlight the ongoing evaluation of cretostimogene as it addresses treatment gaps in intermediate-risk NMIBC.
CG Oncology's Vision for Bladder Cancer Therapy
CG Oncology aspires to transform bladder cancer treatment, envisioning a future where innovative immunotherapies will significantly enhance the quality of life for patients. With a dedication to research and development along with a comprehensive understanding of urological cancers, CG Oncology remains at the forefront of advancements in this field.
Company Contacts for More Information
If you wish to learn more about CG Oncology and their innovative approaches to bladder cancer therapies, the following contacts can provide additional information:
Media Contact:
Sarah Connors
Vice President, Communications and Patient Advocacy
Phone: (508) 654-2277
Investor Relations Contact:
Chau Cheng
Vice President, Investor Relations
Phone: (949) 342-8939
Frequently Asked Questions
What is CG Oncology known for?
CG Oncology specializes in developing treatments for bladder cancer, particularly focusing on innovative immunotherapies.
What is the BOND-003 trial about?
The BOND-003 trial evaluates cretostimogene grenadenorepvec for treating patients with non-muscle invasive bladder cancer who have not responded to prior therapies.
When is the EAU Congress and what is its significance?
The EAU Congress takes place in March and is one of the largest gatherings for urology professionals globally, showcasing advancements in urological research.
Who presents the results at these congresses?
Results are often presented by leading experts in the field, such as oncologists and researchers specializing in urology.
How can interested parties contact CG Oncology?
Interested individuals can reach out via the provided media and investor relations contacts for more information about the company’s initiatives and therapeutics.
